We are passionate about what we do
Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases.
The cornerstone of the Amicus portfolio is GalafoldTM (migalastat). The lead biologics program in the Amicus pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases.